Piramal Pharma Rights Issue will open for subscription from 08 August 2023. the company aims for an issue size of ₹1,050 Crores through this rights Issue.
About the company
Incorporated in 2020, Piramal Pharma Limited a flagship company of Piramal Group offers pharmaceutical products and services across a domestic and global distribution network. The company has 15 global manufacturing facilities and a global distribution network in over 100 countries. Piramal Pharma includes:
- Piramal Pharma Solutions (PPS), is an integrated Contract Development and Manufacturing Organization (CDMO). It develops and manufactures solutions through a globally integrated network of facilities across the drug life cycle for innovators and generic companies.
- Piramal Critical Care (PCC), is a Complex Hospital Generics business whose product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other therapies.
- India Consumer Healthcare (ICH) business, selling over-the-counter products.
Objectives of the Issue
- Repayment or prepayment, in full or in part, of certain borrowings,
- General corporate purposes.
Rights Issue Timetable
| Last Date to buy shares | 01 August 2023 |
| Record Date | 02 August 2023 |
| Credit of Rights Entitlements | |
| Bid/Offer Opens On | 08 August 2023 |
| Renunciation of Rights Entitlements | 10 August 2023 |
| Bid/Offer Closes On | 17 August 2023 |
| Deemed Date of Allotment | 23 August 2023 |
| Credit Date | 24 August 2023 |
| Listing Date | 28 August 2023 |
Piramal Pharma Rights Issue Details
| Issue Open | Aug 8, 2023 – Aug 17, 2023 |
| Security Name | Piramal Pharma Limited |
| Issue Size (Shares) | 129,629,630 |
| Issue Size (Amount) | ₹1,050.00 Crores |
| Issue Price | ₹81 per share |
| Face Value | ₹10 per share |
| Listing At | BSE, NSE |
| Terms of Payment | The full amount of Rs. 81 for rights equity shares has to be paid on application. |
| Entitlement | 5 Rights Equity Share(s) for every 46 fully paid-up Equity Shares held on Record Date |
Company Financials
| Period Ended | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
| Assets | 10,899.78 | 12,797.04 | 14,522.56 |
| Revenue | 6,479.01 | 6,834.90 | 7,306.66 |
| Profit After Tax | 835.03 | 375.96 | -186.46 |
| Net Worth | 5,076.75 | 6,069.94 | 5,968.45 |
| Reserves and Surplus | 4,488.62 | 5,290.69 | 5,181.79 |
| Total Borrowing | 2,910.19 | 4,023.28 | 5,504.77 |
Rights Issue Documents
Lead Manager(s)
- Icici Securities Limited
Rights Issue Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: ppl.rights@linkintime.co.in
Website: https://linkintime.co.in/mipo/ipoallotment.html
Company Contact Information
Piramal Pharma Limited
Ground Floor, Piramal Ananta,
Agastya Corporate Park, Kamani Junction,
LBS Marg, Kurla, Mumbai 400 070
Phone: +91 22 3802 3000
Email: shareholders.ppl@piramal.com
Website: https://www.piramal.com/
Final Thoughts
Applying for the rights issue is purely a personal choice. make sure you make a detailed study about the company and rights issue before you make an investment decision.
Happy investing
